{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,8]],"date-time":"2026-02-08T07:54:39Z","timestamp":1770537279988,"version":"3.49.0"},"reference-count":29,"publisher":"Oxford University Press (OUP)","issue":"12","license":[{"start":{"date-parts":[[2020,5,5]],"date-time":"2020-05-05T00:00:00Z","timestamp":1588636800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100008349","name":"Boehringer Ingelheim","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008349","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004312","name":"Eli Lilly and Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004312","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,12,31]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>BACKGROUND<\/jats:title>\n                  <jats:p>Type 2 diabetes (T2D) and resistant hypertension often coexist, greatly increasing risk of target-organ damage and death. We explored the effects of empagliflozin in patients with and without presumed resistant hypertension (prHT) in a post hoc analysis of EMPA-REG OUTCOME (NCT01131676).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>METHODS<\/jats:title>\n                  <jats:p>Overall, 7,020 patients received empagliflozin 10, 25 mg, or placebo with median follow-up of 3.1 years. We defined baseline prHT as \u22653 classes of antihypertensive drugs including a diuretic and uncontrolled blood pressure (BP; systolic blood pressure (SBP) \u2265140 and\/or diastolic blood pressure \u226590 mm Hg) or \u22654 classes of antihypertensive, including a diuretic, and controlled BP. We explored the effect of empagliflozin on cardiovascular (CV) death, heart failure (HF) hospitalization, 3-point major adverse cardiac events, all-cause death, and incident\/worsening nephropathy by Cox regression and BP over time by a mixed-repeated-measures-model analysis.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>RESULTS<\/jats:title>\n                  <jats:p>1,579 (22.5%) patients had prHT. The mean difference in change in SBP from baseline to week 12 vs. placebo was \u22124.5 (95% confidence interval, \u22125.9 to \u22123.1) mm Hg (P &amp;lt; 0.001) in prHT and \u22123.7 (\u22124.5, \u22122.9) mm Hg (P &amp;lt; 0.001) in patients without prHT. SBP was more frequently controlled (&amp;lt;130\/80 mm Hg) with empagliflozin than with placebo. Patients with prHT had 1.5- to 2-fold greater risk of HF hospitalization, incident\/worsening nephropathy, and CV death compared with those without prHT. Empagliflozin improved all outcomes in patients with and without prHT (interaction P &amp;gt; 0.1 for all outcomes).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>CONCLUSIONS<\/jats:title>\n                  <jats:p>Empagliflozin induced a clinically relevant reduction in SBP and consistently improved all outcomes regardless of prHT status. Due to these dual effects, empagliflozin should be considered for patients with hypertension and T2D.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/ajh\/hpaa073","type":"journal-article","created":{"date-parts":[[2020,4,29]],"date-time":"2020-04-29T11:12:53Z","timestamp":1588158773000},"page":"1092-1101","source":"Crossref","is-referenced-by-count":35,"title":["Empagliflozin for Patients With Presumed Resistant Hypertension: A <i>Post Hoc<\/i> Analysis of the EMPA-REG OUTCOME Trial"],"prefix":"10.1093","volume":"33","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2304-6138","authenticated-orcid":false,"given":"Jo\u00e3o Pedro","family":"Ferreira","sequence":"first","affiliation":[{"name":"Universit\u00e9 de Lorraine, Centre d\u2019Investigations Cliniques Plurith\u00e9matique Inserm 1433 , Nancy, France"},{"name":"CHRU de Nancy, Inserm U1116 , Nancy, France"},{"name":"FCRIN INI-CRCT , Nancy, France"}]},{"given":"David","family":"Fitchett","sequence":"additional","affiliation":[{"name":"Division of Cardiology, St Michael\u2019s Hospital, University of Toronto , Toronto, Ontario, Canada"}]},{"given":"Anne Pernille","family":"Ofstad","sequence":"additional","affiliation":[{"name":"Boehringer Ingelheim Norway KS , Asker, Norway"}]},{"given":"Bettina Johanna","family":"Kraus","sequence":"additional","affiliation":[{"name":"Comprehensive Heart Failure Center, University of W\u00fcrzburg , W\u00fcrzburg, Germany"},{"name":"Department of Internal Medicine I, University Hospital W\u00fcrzburg , W\u00fcrzburg, Germany"}]},{"given":"Christoph","family":"Wanner","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine I, University Hospital W\u00fcrzburg , W\u00fcrzburg, Germany"}]},{"given":"Isabella","family":"Zwiener","sequence":"additional","affiliation":[{"name":"Boehringer Ingelheim Pharma GmbH & Co. KG , Ingelheim, Germany"}]},{"given":"Bernard","family":"Zinman","sequence":"additional","affiliation":[{"name":"Lunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital, University of Toronto , Toronto, Ontario, Canada"}]},{"given":"Sabine","family":"Lauer","sequence":"additional","affiliation":[{"name":"Boehringer Ingelheim Pharma GmbH & Co. KG , Ingelheim, Germany"}]},{"given":"Jyothis T","family":"George","sequence":"additional","affiliation":[{"name":"Boehringer Ingelheim International GmbH , Ingelheim, Germany"}]},{"given":"Patrick","family":"Rossignol","sequence":"additional","affiliation":[{"name":"Universit\u00e9 de Lorraine, Centre d\u2019Investigations Cliniques Plurith\u00e9matique Inserm 1433 , Nancy, France"},{"name":"CHRU de Nancy, Inserm U1116 , Nancy, France"},{"name":"FCRIN INI-CRCT , Nancy, France"}]},{"given":"Faiez","family":"Zannad","sequence":"additional","affiliation":[{"name":"Universit\u00e9 de Lorraine, Centre d\u2019Investigations Cliniques Plurith\u00e9matique Inserm 1433 , Nancy, France"},{"name":"CHRU de Nancy, Inserm U1116 , Nancy, France"},{"name":"FCRIN INI-CRCT , Nancy, France"}]}],"member":"286","published-online":{"date-parts":[[2020,5,5]]},"reference":[{"key":"2023120723275554100_CIT0001","doi-asserted-by":"crossref","first-page":"S86","DOI":"10.2337\/dc18-S009","article-title":"9. Cardiovascular disease and risk management: standards of medical care in diabetes\u20142018","volume":"41","author":"American Diabetes Association","year":"2018","journal-title":"Diabetes Care"},{"key":"2023120723275554100_CIT0002","first-page":"e484","article-title":"2017 ACC\/AHA\/AAPA\/ABC\/ACPM\/AGS\/APhA\/ASH\/ASPC\/NMA\/PCNA Guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: a report of the American College of Cardiology\/American Heart Association task force on clinical practice guidelines","volume":"138","author":"Whelton","year":"2018","journal-title":"Circulation"},{"key":"2023120723275554100_CIT0003","doi-asserted-by":"crossref","first-page":"1953","DOI":"10.1097\/HJH.0000000000001940","article-title":"2018 ESC\/ESH Guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Cardiology and the European Society of Hypertension","volume":"36","author":"Williams","year":"2018","journal-title":"J Hypertens"},{"key":"2023120723275554100_CIT0004","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.117.006745","article-title":"Resistant hypertension, time-updated blood pressure values and renal outcome in Type 2 diabetes mellitus","volume":"6","author":"Viazzi","year":"2017","journal-title":"J Am Heart Assoc"},{"key":"2023120723275554100_CIT0005","first-page":"e53","article-title":"Resistant hypertension: detection, evaluation, and management: a scientific statement from the American Heart Association","volume":"72","author":"Carey","year":"2018","journal-title":"Hypertension (Dallas, Tex.: 1979)"},{"key":"2023120723275554100_CIT0006","first-page":"e426","article-title":"2017 ACC\/AHA\/AAPA\/ABC\/ACPM\/AGS\/APhA\/ASH\/ASPC\/NMA\/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: executive summary: a report of the American College of Cardiology\/American Heart Association Task Force on clinical practice guidelines","volume":"138","author":"Whelton","year":"2018","journal-title":"Circulation"},{"key":"2023120723275554100_CIT0007","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1161\/CIRCULATIONAHA.111.068064","article-title":"Incidence and prognosis of resistant hypertension in hypertensive patients","volume":"125","author":"Daugherty","year":"2012","journal-title":"Circulation"},{"key":"2023120723275554100_CIT0008","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.ahj.2016.08.002","article-title":"Diabetes, diabetes severity, and coronary heart disease risk equivalence: REasons for Geographic and Racial Differences in Stroke (REGARDS)","volume":"181","author":"Mondesir","year":"2016","journal-title":"Am Heart J"},{"key":"2023120723275554100_CIT0009","doi-asserted-by":"crossref","first-page":"2686","DOI":"10.1093\/eurheartj\/ehv392","article-title":"Resistant hypertension: what the cardiologist needs to know","volume":"36","author":"Rimoldi","year":"2015","journal-title":"Eur Heart J"},{"key":"2023120723275554100_CIT0010","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes","volume":"373","author":"Zinman","year":"2015","journal-title":"N Engl J Med"},{"key":"2023120723275554100_CIT0011","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1161\/HYPERTENSIONAHA.119.12676","article-title":"Emerging drug classes and their potential use in hypertension","volume":"74","author":"Azizi","year":"2019","journal-title":"Hypertension"},{"key":"2023120723275554100_CIT0012","doi-asserted-by":"crossref","first-page":"420","DOI":"10.2337\/dc14-1096","article-title":"Empagliflozin reduces blood pressure in patients with type 2 diabetes and hypertension","volume":"38","author":"Tikkanen","year":"2015","journal-title":"Diabetes Care"},{"key":"2023120723275554100_CIT0013","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1161\/HYPERTENSIONAHA.116.07703","article-title":"Impact of empagliflozin on blood pressure in patients with type 2 diabetes mellitus and hypertension by background antihypertensive medication","volume":"68","author":"Mancia","year":"2016","journal-title":"Hypertension (Dallas, Tex.: 1979)"},{"key":"2023120723275554100_CIT0014","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1186\/1475-2840-13-28","article-title":"The effect of empagliflozin on arterial stiffness and heart rate variability in subjects with uncomplicated type 1 diabetes mellitus","volume":"13","author":"Cherney","year":"2014","journal-title":"Cardiovasc Diabetol"},{"key":"2023120723275554100_CIT0015","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1111\/dom.12572","article-title":"Effects of empagliflozin on blood pressure and markers of arterial stiffness and vascular resistance in patients with type 2 diabetes","volume":"17","author":"Chilton","year":"2015","journal-title":"Diabetes Obes Metab"},{"key":"2023120723275554100_CIT0016","doi-asserted-by":"crossref","first-page":"356","DOI":"10.2337\/dc17-1096","article-title":"How does empagliflozin reduce cardiovascular mortality? Insights from a mediation analysis of the EMPA-REG OUTCOME Trial","volume":"41","author":"Inzucchi","year":"2018","journal-title":"Diabetes Care"},{"key":"2023120723275554100_CIT0017","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1007\/s11892-014-0516-y","article-title":"Resistant hypertension in diabetes mellitus","volume":"14","author":"Bayliss","year":"2014","journal-title":"Curr Diab Rep"},{"key":"2023120723275554100_CIT0018","doi-asserted-by":"crossref","first-page":"2560","DOI":"10.1001\/jama.289.19.2560","article-title":"The seventh report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure: the JNC 7 report","volume":"289","author":"Chobanian","year":"2003","journal-title":"JAMA"},{"key":"2023120723275554100_CIT0019","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1056\/NEJMoa1001286","article-title":"Effects of intensive blood-pressure control in type 2 diabetes mellitus","volume":"362","author":"Cushman","year":"2010","journal-title":"N Engl J Med"},{"key":"2023120723275554100_CIT0020","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/S0140-6736(15)00805-3","article-title":"Effects of intensive blood pressure lowering on cardiovascular and renal outcomes: updated systematic review and meta-analysis","volume":"387","author":"Xie","year":"2016","journal-title":"Lancet"},{"key":"2023120723275554100_CIT0021","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1161\/HYPERTENSIONAHA.117.10713","article-title":"Intensive blood pressure targets for diabetic and other high-risk populations: a pooled individual patient data analysis","volume":"71","author":"Aggarwal","year":"2018","journal-title":"Hypertension (Dallas, Tex.: 1979)"},{"key":"2023120723275554100_CIT0022","doi-asserted-by":"crossref","first-page":"2103","DOI":"10.1056\/NEJMoa1511939","article-title":"A randomized trial of intensive versus standard blood-pressure control","volume":"373","author":"Wright","year":"2015","journal-title":"N Engl J Med"},{"key":"2023120723275554100_CIT0023","doi-asserted-by":"crossref","first-page":"2059","DOI":"10.1016\/S0140-6736(15)00257-3","article-title":"Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trial","volume":"386","author":"Williams","year":"2015","journal-title":"Lancet"},{"key":"2023120723275554100_CIT0024","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1097\/HJH.0000000000001977","article-title":"Regression to the mean of repeated ambulatory blood pressure monitoring five studies","volume":"37","author":"Moore","year":"2019","journal-title":"J Hypertens"},{"key":"2023120723275554100_CIT0025","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1093\/ajh\/hpx210","article-title":"Spironolactone and resistant hypertension in heart failure with preserved ejection fraction","volume":"31","author":"Rossignol","year":"2018","journal-title":"Am J Hypertens"},{"key":"2023120723275554100_CIT0026","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1016\/S0140-6736(19)32135-X","article-title":"Patiromer versus placebo to enable spironolactone use in patients with resistant hypertension and chronic kidney disease (AMBER): a phase 2, randomised, double-blind, placebo-controlled trial","volume":"394","author":"Agarwal","year":"2019","journal-title":"Lancet"},{"key":"2023120723275554100_CIT0027","doi-asserted-by":"crossref","first-page":"93","DOI":"10.3109\/08037051.2015.1116258","article-title":"Effects of dapagliflozin on blood pressure in hypertensive diabetic patients on renin-angiotensin system blockade","volume":"25","author":"Weber","year":"2016","journal-title":"Blood Press"},{"key":"2023120723275554100_CIT0028","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1111\/jch.12425","article-title":"Effect of canagliflozin on blood pressure and adverse events related to osmotic diuresis and reduced intravascular volume in patients with type 2 diabetes mellitus","volume":"16","author":"Weir","year":"2014","journal-title":"J Clin Hypertens (Greenwich)"},{"key":"2023120723275554100_CIT0029","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1161\/CIRCULATIONAHA.117.028268","article-title":"Empagliflozin and clinical outcomes in patients with type 2 diabetes mellitus, established cardiovascular disease, and chronic kidney disease","volume":"137","author":"Wanner","year":"2018","journal-title":"Circulation"}],"container-title":["American Journal of Hypertension"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/ajh\/advance-article-pdf\/doi\/10.1093\/ajh\/hpaa073\/33227150\/hpaa073.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ajh\/article-pdf\/33\/12\/1092\/54093620\/hpaa073.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ajh\/article-pdf\/33\/12\/1092\/54093620\/hpaa073.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,8]],"date-time":"2023-12-08T00:31:51Z","timestamp":1701995511000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ajh\/article\/33\/12\/1092\/5830772"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5,5]]},"references-count":29,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2020,5,5]]},"published-print":{"date-parts":[[2020,12,31]]}},"URL":"https:\/\/doi.org\/10.1093\/ajh\/hpaa073","relation":{},"ISSN":["0895-7061","1941-7225"],"issn-type":[{"value":"0895-7061","type":"print"},{"value":"1941-7225","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2020,12,1]]},"published":{"date-parts":[[2020,5,5]]}}}